Evidence for prevention of renal dysfunction associated with primary myelofibrosis by cytoreductive therapy.
作者信息
Fukuda Yasutaka, Araki Marito, Yamamoto Kouji, Morishita Soji, Inano Tadaaki, Misawa Kyohei, Ochiai Tomonori, Edahiro Yoko, Imai Misa, Yasuda Hajime, Gotoh Akihiko, Ohsaka Akimichi, Komatsu Norio
机构信息
Department of Hematology, Juntendo University Graduate School of Medicine, Tokyo.
Department of Transfusion Medicine and Stem Cell Regulation, Juntendo University Graduate School of Medicine, Tokyo.
出版信息
Haematologica. 2019 Nov;104(11):e506-e509. doi: 10.3324/haematol.2018.208876. Epub 2019 Apr 4.
Abstract
摘要
相似文献
1
Evidence for prevention of renal dysfunction associated with primary myelofibrosis by cytoreductive therapy.通过细胞减灭疗法预防原发性骨髓纤维化相关肾功能不全的证据。
Haematologica. 2019 Nov;104(11):e506-e509. doi: 10.3324/haematol.2018.208876. Epub 2019 Apr 4.
2
Postoperative renal insufficiency.
Med Clin North Am. 2001 Sep;85(5):1241-54. doi: 10.1016/s0025-7125(05)70375-8.
3
The impact of residual renal function on the adequacy of peritoneal dialysis.
Contrib Nephrol. 1998;124:76-93; discussion 93-102. doi: 10.1159/000059932.
4
Simple renal cysts in the solitary kidney: Are they innocent in adult patients?孤立肾中的单纯性肾囊肿：它们在成年患者中是无害的吗？
Nephrology (Carlton). 2017 May;22(5):361-365. doi: 10.1111/nep.12778.
5
Prediction of glomerular filtration rate decline in diabetic subjects with impaired renal function.
Nephrol Dial Transplant. 2007 Mar;22(3):959-60; author reply 960. doi: 10.1093/ndt/gfl723. Epub 2006 Dec 19.
6
Diabetic nephropathy: strategies for preventing renal failure.
Cleve Clin J Med. 1996 Oct;63(6):331-8. doi: 10.3949/ccjm.63.6.331.
7
Preoperative Proteinuria and Reduced Glomerular Filtration Rate Predicts Renal Replacement Therapy in Patients Supported With Continuous-Flow Left Ventricular Assist Devices.术前蛋白尿和肾小球滤过率降低可预测接受连续流左心室辅助装置支持的患者的肾脏替代治疗。
Circ Heart Fail. 2016 Dec;9(12). doi: 10.1161/CIRCHEARTFAILURE.115.002897.
8
Measured and estimated glomerular filtration rate.
N Engl J Med. 2006 Sep 7;355(10):1068-9; author reply 1069-70.
9
Screening tests for renal impairment in patients with type 2 diabetes: the what, when, and how.2 型糖尿病患者的肾功能损害筛查试验：内容、时机和方法。
Postgrad Med. 2011 Jan;123(1):7-14. doi: 10.3810/pgm.2011.01.2240.
10
Measured and estimated glomerular filtration rate.
N Engl J Med. 2006 Sep 7;355(10):1069; author reply 1069-70.
引用本文的文献
1
Presence and Onset of Chronic Kidney Disease as a Factor Involved in the Poor Prognosis of Patients with Essential Thrombocythemia.慢性肾脏病的存在及发病作为原发性血小板增多症患者预后不良的一个相关因素
Adv Hematol. 2024 Feb 8;2024:9591497. doi: 10.1155/2024/9591497. eCollection 2024.
2
Optimization of cardiovascular risk factor management in patients with BCR::ABL1 negative chronic myeloproliferative neoplasms, current knowledge, and perspectives.BCR::ABL1 阴性慢性骨髓增殖性肿瘤患者心血管风险因素管理的优化：现有知识和观点。
Ann Hematol. 2024 May;103(5):1513-1523. doi: 10.1007/s00277-023-05426-9. Epub 2023 Sep 4.
3
Higher JAK2 V617F mutant allele burden in patients with chronic myeloproliferative neoplasms is associated with a higher prevalence of chronic kidney disease and unfavorable dynamics of kidney function over time.慢性骨髓增殖性肿瘤患者中较高的JAK2 V617F突变等位基因负荷与慢性肾脏病的较高患病率以及肾功能随时间的不利变化相关。
Ann Hematol. 2023 Jul;102(7):1955-1956. doi: 10.1007/s00277-023-05305-3. Epub 2023 Jun 3.
4
Kidney Dysfunction Is Associated with Thrombosis and Disease Severity in Myeloproliferative Neoplasms: Implications from the German Study Group for MPN Bioregistry.肾功能不全与骨髓增殖性肿瘤中的血栓形成及疾病严重程度相关：来自德国骨髓增殖性肿瘤生物注册研究组的启示
Cancers (Basel). 2021 Aug 13;13(16):4086. doi: 10.3390/cancers13164086.
5
Beneficial effect of ACE inhibitors on kidney function in polycythemia vera.血管紧张素转换酶抑制剂对真性红细胞增多症患者肾功能的有益作用。
Wien Klin Wochenschr. 2021 Aug;133(15-16):808-815. doi: 10.1007/s00508-021-01812-3. Epub 2021 Feb 8.
6
Reduced renal function strongly affects survival and thrombosis in patients with myelofibrosis.肾功能降低强烈影响骨髓纤维化患者的生存和血栓形成。
Ann Hematol. 2020 Dec;99(12):2779-2785. doi: 10.1007/s00277-020-04239-4. Epub 2020 Aug 29.
7
Pharmacokinetics and tolerability of fedratinib, an oral, selective Janus kinase 2 inhibitor, in subjects with renal or hepatic impairment.口服、选择性 Janus 激酶 2 抑制剂 fedratinib 在肾或肝损伤受试者中的药代动力学和耐受性。
Cancer Chemother Pharmacol. 2020 Jun;85(6):1109-1117. doi: 10.1007/s00280-020-04084-2. Epub 2020 May 24.
本文引用的文献
1
Chronic kidney disease in the BCR-ABL1-negative myeloproliferative neoplasm: a single-center retrospective study.BCR-ABL1 阴性骨髓增殖性肿瘤中的慢性肾脏病：一项单中心回顾性研究
Korean J Intern Med. 2018 Jul;33(4):790-797. doi: 10.3904/kjim.2016.263. Epub 2017 Mar 17.
2
Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms.经典骨髓增殖性肿瘤的遗传学基础和分子病理生理学。
Blood. 2017 Feb 9;129(6):667-679. doi: 10.1182/blood-2016-10-695940. Epub 2016 Dec 27.
3
Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms.经典型骨髓增殖性肿瘤的诊断、风险分层及反应评估
Blood. 2017 Feb 9;129(6):680-692. doi: 10.1182/blood-2016-10-695957. Epub 2016 Dec 27.
4
Oxidant Mechanisms in Renal Injury and Disease.肾脏损伤与疾病中的氧化机制
Antioxid Redox Signal. 2016 Jul 20;25(3):119-46. doi: 10.1089/ars.2016.6665. Epub 2016 Apr 26.
5
Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both.骨髓增殖性肿瘤与炎症：靶向恶性克隆还是炎症过程，或者两者兼而有之。
Leukemia. 2016 May;30(5):1018-24. doi: 10.1038/leu.2016.12. Epub 2016 Feb 8.
6
Renal extramedullary hematopoiesis: interstitial and glomerular pathology.肾外髓造血：间质及肾小球病变
Mod Pathol. 2015 Dec;28(12):1574-83. doi: 10.1038/modpathol.2015.117. Epub 2015 Oct 9.
7
Volume regulation and renal function at high altitude across gender.高海拔地区不同性别间的容量调节与肾功能
PLoS One. 2015 Mar 5;10(3):e0118730. doi: 10.1371/journal.pone.0118730. eCollection 2015.
8
JAK2, CALR, and MPL mutation spectrum in Japanese patients with myeloproliferative neoplasms.日本骨髓增殖性肿瘤患者的JAK2、CALR和MPL基因突变谱
Haematologica. 2015 Feb;100(2):e46-8. doi: 10.3324/haematol.2014.115113. Epub 2014 Nov 14.
9
Chronic kidney disease in patients with the Philadelphia-negative chronic myeloproliferative neoplasms.费城阴性慢性骨髓增殖性肿瘤患者的慢性肾脏病。
Leuk Res. 2014 Apr;38(4):490-5. doi: 10.1016/j.leukres.2014.01.014. Epub 2014 Feb 4.
10
A role for reactive oxygen species in JAK2 V617F myeloproliferative neoplasm progression.活性氧在 JAK2 V617F 骨髓增殖性肿瘤进展中的作用。
Leukemia. 2013 Nov;27(11):2187-95. doi: 10.1038/leu.2013.102. Epub 2013 Apr 5.
Zotero 插件